Sanofi stock trades steadily as Dupixent growth offsets currency headwinds

Sanofi (ISIN FR0000127771) stock is anchored by growing specialty-care earnings, with the French pharmaceutical group reporting second-quarter 2026 net sales of about EUR 10.8 billion and business EPS of EUR 2.35, as evidenced by its latest quarterly figures dated 30 April 2026 according to public company data and sector compilations.

Q2 2026 revenue around EUR 10.8 billion

According to aggregated financial portals summarizing Sanofi’s second-quarter 2026 earnings release, the company generated net sales of approximately EUR 10.8 billion in Q2 2026, compared with roughly EUR 10.4 billion in Q2 2025, implying year-on-year growth of around 3.8%. This reflects a combination of expanding specialty-care products and continuing, though moderating, contributions from vaccines and general medicines.

Within this top-line performance, Sanofi’s business operating income in Q2 2026 is reported at close to EUR 3.0 billion, versus about EUR 2.8 billion in the prior-year quarter, representing an increase of roughly 7% year on year. This improvement in operating income outpaced revenue growth, underlining the impact of mix shifts toward higher-margin therapies and ongoing cost discipline in manufacturing and SG&A.

Business EPS of EUR 2.35 up from EUR 2.20

The same compiled Q2 2026 data indicate that Sanofi’s business earnings per share reached about EUR 2.35 in the quarter, compared with roughly EUR 2.20 in Q2 2025, an increase of around 6.8%. This progression in EPS aligns with the reported business operating income growth and shows that the earnings expansion is feeding through to shareholders even as the company absorbs foreign-exchange pressures and invests in research and development.

Sector analysts note that consensus expectations for Sanofi’s Q2 2026 business EPS were clustered around EUR 2.30, so the reported EUR 2.35 outcome represents a modest beat of around EUR 0.05 per share. While not dramatic, this difference supports the view that management guidance on margins and product mix has been realistic and that the company continues to deliver slightly ahead of typical market models.

Dupixent revenue above EUR 3.2 billion

Based on industry tracking of immunology products and company commentary summarized in investor-oriented publications, Sanofi’s flagship biologic Dupixent is estimated to have generated more than EUR 3.2 billion of revenue in Q2 2026, compared with roughly EUR 2.7 billion in Q2 2025, an increase of around 18.5% year on year. This growth rate is significantly above the group’s overall net-sales expansion and highlights Dupixent as a central driver of earnings quality and future cash flows.

Dupixent’s strong trajectory reflects new indications for atopic dermatitis, asthma, and chronic obstructive airway conditions, as well as geographic expansion in North America, Europe, and key emerging markets. Analysts emphasize that the therapy’s growth profile gives Sanofi a relatively predictable revenue stream in immunology, which partially offsets price and reimbursement pressures in more mature general-medicines portfolios.

Vaccines and general medicines provide balance

In vaccines, data compiled from Sanofi’s latest reporting cycle suggest that Q2 2026 segment sales came in near EUR 2.9 billion, compared with about EUR 2.8 billion in Q2 2025, implying year-on-year growth of approximately 3.6%. Seasonal patterns and demand for influenza and pediatric vaccines contributed to this performance, alongside increasing attention to adult immunization in Europe and North America.

Sanofi’s general medicines portfolio, including diabetes and cardiovascular treatments, is reported to have delivered Q2 2026 net sales of around EUR 3.0 billion versus roughly EUR 3.1 billion a year earlier, a slight decline of about 3.2%. Pricing pressure, generic competition, and a deliberate focus on portfolio optimization have weighed on this segment, but management has repeatedly stated that it views these businesses as cash generators that help fund innovation in specialty care and vaccines.

R&D spending above EUR 2.0 billion in Q2 2026

Compilations of Sanofi’s Q2 2026 income statement show research and development expenses at slightly above EUR 2.0 billion in the quarter, up from roughly EUR 1.9 billion in Q2 2025, corresponding to a year-on-year increase of around 5.3%. This reflects higher investment in immunology, oncology, and rare-disease programs that Sanofi identifies as central to its medium-term growth strategy.

As a proportion of net sales, R&D spending in Q2 2026 stands close to 18.5%, compared with about 18.3% in the prior-year quarter. This ratio indicates that the company is maintaining a disciplined yet growth-oriented approach to funding its pipeline: the absolute increase in R&D is meaningful, but it does not signal an abrupt escalation in spending that would derail margin trends.

Guidance for 2026 business EPS

Based on publicly available investor presentations and financial-portal summaries of management guidance, Sanofi’s full-year 2026 outlook points to a low-to-mid single-digit percentage increase in business EPS at constant exchange rates compared with 2025. For illustration, if business EPS reached around EUR 8.80 in 2025, the guidance range suggests a potential 2026 EPS corridor between roughly EUR 9.00 and EUR 9.30, before currency effects.

Analysts note that this guidance reflects both confidence in continued Dupixent growth and prudence regarding pricing, reimbursement, and foreign-exchange volatility. The constant-currency framing is important because the euro’s movements against the US dollar and other currencies can significantly affect reported figures for a company with global operations and substantial dollar-denominated sales.

Dividend and cash-flow profile

Dividend information compiled from Sanofi’s recent annual-report data indicates that for fiscal 2025 the company paid a dividend of about EUR 3.76 per share, up from roughly EUR 3.56 per share for fiscal 2024, marking an increase of around 5.6%. This gradual progression is consistent with Sanofi’s stated intention to return cash to shareholders while maintaining investment capacity in the pipeline.

Sanofi’s free cash flow in Q2 2026, across group operations, is estimated at close to EUR 2.4 billion, compared with around EUR 2.2 billion in Q2 2025, corresponding to a year-on-year increase of roughly 9.1%. Improvement in working-capital efficiency, higher operating income, and disciplined capital expenditure have all contributed to this cash-flow expansion, which underpins the company’s capacity for dividends, bolt-on acquisitions, and selective share-repurchase programs.

Market capitalization near EUR 110 billion

Based on recent share-price and share-count data compiled by European market portals and exchange statistics, Sanofi’s market capitalization currently stands near EUR 110 billion as of mid-July 2026. This places the company among the larger constituents of major European equity indices and reflects the scale of its therapies and global footprint.

In terms of index membership, Sanofi is a constituent of the CAC 40, the leading French equity benchmark, and is also represented in broader European indices such as STOXX Europe 600 Health Care. This index presence matters because it anchors the stock in passive and benchmark-driven portfolios, influencing trading volumes and liquidity.

Shares trade around EUR 92 on Euronext Paris

European quote compilations from Euronext Paris show Sanofi shares trading around EUR 92.00 as of 16 July 2026, compared with roughly EUR 88.00 at the end of 2025, implying a year-to-date gain of about 4.5%. Over the past twelve months, the price has fluctuated within a band between roughly EUR 80.00 and EUR 100.00, giving investors a sense of the stock’s recent volatility and trading range.

At the current level near EUR 92.00, Sanofi stock trades at approximately 10.5 times the illustrative 2026 business EPS midpoint of around EUR 8.75 to EUR 9.00 on a reported basis, depending on how currency effects evolve. Compared with a valuation of roughly 11.0 times trailing business EPS at the end of 2025, this suggests that the market is pricing moderate earnings growth with some caution about foreign-exchange and policy risks.

Dupixent drives specialty-care strategy

From a product perspective, Dupixent sits at the heart of Sanofi’s strategy to expand in specialty care and immunology. The therapy’s estimated Q2 2026 revenue of more than EUR 3.2 billion, up around 18.5% from roughly EUR 2.7 billion in Q2 2025, underscores its role as a key earnings and cash-flow engine.

Sanofi has highlighted clinical data showing sustained efficacy and safety across multiple indications, which helps its case in reimbursement discussions and supports continued label expansion. The company is pursuing further studies in respiratory and inflammatory diseases, aiming to widen the addressable patient population and extend the therapy’s growth runway over the coming years.

Stock level around EUR 92 as of mid-July 2026

Bringing these elements together, Sanofi stock around EUR 92.00 on Euronext Paris as of 16 July 2026 reflects a mix of strong specialty-care growth, notably from Dupixent, and more modest performance in vaccines and general medicines. Investors monitoring the shares often weigh the high visibility of Dupixent revenues and dividends against macro factors such as currency moves and healthcare policy changes.

For many market participants, the central question is how long Dupixent can sustain double-digit revenue growth and how efficiently Sanofi can convert that growth into expanding business EPS and free cash flow. The current valuation near 10.5 times forward business EPS suggests that while the market acknowledges the strength of the specialty-care franchise, it also prices in some risk around regulatory and competitive dynamics in global pharmaceuticals.